DOSING & STORAGE

Here’s what you should know about the dosing, storage, and preparation of SHINGRIX before vaccinating your patients.

SHINGRIX prefilled syringe

THE SHINGRIX PREFILLED SYRINGE PRESENTATION IS DESIGNED FOR YOUR CONVENIENCE

  • Fully liquid1
  • No reconstitution required1

Compare SHINGRIX presentations

 
PREFILLED SYRINGE
VIAL AND VIAL
Reconstitution needed No Yes
Volume of single dose1 0.5 mL* 0.5 mL (after reconstitution)
Number of units per pack 10 prefilled syringes (10 doses) 20 vials (10 doses)
Pack dimensions 9.9 x 17.7 x 2.0 cm (350 cm3) 9.0 x 7.5 x 4.2 cm (284 cm3)
CPT code2,† 90750 Same
NDC (10-dose carton)1,‡ 58160-849-52 58160-823-11
  • *

    SHINGRIX is available as 0.5-mL single-dose, disposable, prefilled TIP-LOK syringes (Luer Lock syringes) packaged without needles. TIP-LOK syringes are to be used with Luer Lock compatible needles.

  • †

    This information is not intended to serve as comprehensive training on medical billing and coding. Users should independently verify accuracy. Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

  • ‡

    Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.

Continue using the unexpired vial and vial presentation of SHINGRIX until your inventory runs out

We're here to help you during the switch from SHINGRIX vials to prefilled syringes. For questions and more information, visit us at contactus.gsk.com or call the GSK Response Center at 1-800-772-9292.

Actor portrayal.

DOSING SCHEDULE

SHINGRIX is administered intramuscularly as a 2-dose series1

It is important to receive both doses. The efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series.1

Dosing schedule

Administer the first dose at Month 0 followed by a second dose 2 to 6 months later.1

Dosing schedule: administer the first dose at Month 0 followed by a second dose 2 to 6 months later
PREFILLED SYRINGE FACT SHEET

Alternative dosing schedule

For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: administer a first dose at Month 0 followed by a second dose 1 to 2 months later.1

Alternative dosing schedule: administer a first dose at Month 0 followed by a second dose 1 to 2 months later

Follow up on the second dose

Your patients count on you and your staff to help them complete their 2-dose series of SHINGRIX

 

How to help your patients stay accountable:

  • Document your discussion
  • Encourage them to schedule their second-dose appointment at your practice or at a pharmacy by visiting ScheduleSHINGRIX.com
  • Follow up to ensure they received both doses of SHINGRIX
Scheduleshingrix.com

STORAGE

SHINGRIX prefilled syringe

Prefilled syringe

Storage instructions for the prefilled syringe

 

PRIOR TO ADMINISTRATION

Store the SHINGRIX prefilled syringe refrigerated between 2°C and 8°C (36°F and 46°F). Protect from light. Do not freeze. Discard if frozen.1

Liquid and powder vials used to reconstitute SHINGRIX

Vial and vial

SHINGRIX is supplied as an adjuvant and antigen for reconstitution

Prepare SHINGRIX by reconstituting a single-dose vial of Lyophilized gE Antigen Component (powder) with a single-dose vial of Adjuvant Suspension Component (liquid).1

 

PRIOR TO RECONSTITUTION

Store both the Antigen (powder) and Adjuvant Suspension (liquid) Components refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze; discard if frozen and protect from light.1

 

AFTER RECONSTITUTION

Administer immediately or store refrigerated between 2°C and 8°C (36°F and 46°F) for up to 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze; discard if frozen.1

  •  

    gE=glycoprotein E.

PREPARATION

Watch instructions on proper administration and storage of SHINGRIX

Video thumbnail: Prefilled syringe presentationVideo Icon
Watch Now

SHINGRIX prefilled syringes — no reconstitution required.1

Please refer to the full Prescribing Information for SHINGRIX for full details.

Video thumbnail: ReconstitutionVideo Icon
Watch Now

How to reconstitute the vial and vial presentation of SHINGRIX.

Please refer to the full Prescribing Information for SHINGRIX for full details.

You may also be interested in:

Incidence of Shingles

Learn about the incidence of shingles in immunocompromised patients aged 18 years and older.

VIEW THE NUMBERS

CDC Recommendations

See what CDC says about SHINGRIX. 

LEARN MORE

Safety Profile

Learn about the safety profile of SHINGRIX in immunocompromised patients aged 18 years and older.

SAFETY INFO

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Prescribing Information for SHINGRIX.

  2. Immunization Information Systems: CPT codes mapped to CVX codes. Centers for Disease Control and Prevention. Reviewed November 26, 2025. Accessed January 12, 2026. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET